Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, Shimizu N, Horiguchi S, Okamoto Y, Fujii S, Taniguchi M, Fujisawa T, Nakayama T. Motohashi S, et al. Among authors: hanaoka h. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6079-86. doi: 10.1158/1078-0432.CCR-06-0114. Epub 2006 Oct 6. Clin Cancer Res. 2006. PMID: 17028247 Clinical Trial.
A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, Nakayama T. Motohashi S, et al. Among authors: hanaoka h. J Immunol. 2009 Feb 15;182(4):2492-501. doi: 10.4049/jimmunol.0800126. J Immunol. 2009. PMID: 19201905 Clinical Trial.
Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells.
Nagato K, Motohashi S, Ishibashi F, Okita K, Yamasaki K, Moriya Y, Hoshino H, Yoshida S, Hanaoka H, Fujii S, Taniguchi M, Yoshino I, Nakayama T. Nagato K, et al. Among authors: hanaoka h. J Clin Immunol. 2012 Oct;32(5):1071-81. doi: 10.1007/s10875-012-9697-9. Epub 2012 Apr 26. J Clin Immunol. 2012. PMID: 22534863 Clinical Trial.
Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer.
Toyoda T, Kamata T, Tanaka K, Ihara F, Takami M, Suzuki H, Nakajima T, Ikeuchi T, Kawasaki Y, Hanaoka H, Nakayama T, Yoshino I, Motohashi S. Toyoda T, et al. Among authors: hanaoka h. J Immunother Cancer. 2020 Mar;8(1):e000316. doi: 10.1136/jitc-2019-000316. J Immunother Cancer. 2020. PMID: 32188702 Free PMC article. Clinical Trial.
Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan.
Kageyama T, Ikeda K, Tanaka S, Taniguchi T, Igari H, Onouchi Y, Kaneda A, Matsushita K, Hanaoka H, Nakada TA, Ohtori S, Yoshino I, Matsubara H, Nakayama T, Yokote K, Nakajima H. Kageyama T, et al. Among authors: hanaoka h. Clin Microbiol Infect. 2021 Dec;27(12):1861.e1-1861.e5. doi: 10.1016/j.cmi.2021.07.042. Epub 2021 Aug 8. Clin Microbiol Infect. 2021. PMID: 34375755 Free PMC article.
Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2-induced lung exudative vasculitis and predicts COVID-19 severity.
Iwamura C, Hirahara K, Kiuchi M, Ikehara S, Azuma K, Shimada T, Kuriyama S, Ohki S, Yamamoto E, Inaba Y, Shiko Y, Aoki A, Kokubo K, Hirasawa R, Hishiya T, Tsuji K, Nagaoka T, Ishikawa S, Kojima A, Mito H, Hase R, Kasahara Y, Kuriyama N, Tsukamoto T, Nakamura S, Urushibara T, Kaneda S, Sakao S, Tobiume M, Suzuki Y, Tsujiwaki M, Kubo T, Hasegawa T, Nakase H, Nishida O, Takahashi K, Baba K, Iizumi Y, Okazaki T, Kimura MY, Yoshino I, Igari H, Nakajima H, Suzuki T, Hanaoka H, Nakada TA, Ikehara Y, Yokote K, Nakayama T. Iwamura C, et al. Among authors: hanaoka h. Proc Natl Acad Sci U S A. 2022 Aug 16;119(33):e2203437119. doi: 10.1073/pnas.2203437119. Epub 2022 Jul 27. Proc Natl Acad Sci U S A. 2022. PMID: 35895716 Free PMC article.
Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study.
Okonogi N, Usui H, Murata K, Hori M, Kurokawa T, Fujiwara T, Fujii Y, Hanawa M, Kawasaki Y, Hattori Y, Suzuki K, Tsuyuki K, Wakatsuki M, Hasegawa S, Yamada S, Hanaoka H, Shozu M, Tsuji H. Okonogi N, et al. Among authors: hanaoka h. BMJ Open. 2022 Mar 2;12(3):e056424. doi: 10.1136/bmjopen-2021-056424. BMJ Open. 2022. PMID: 35236732 Free PMC article.
353 results